Abstract

Within the Interstitial Lung Diseases (ILD), patients with idiopathic pulmonary fibrosis (IPF) and a subset of those with non-IPF fibrotic ILD have a distinct clinical phenotype of progression despite management. This group of patients has been collectively termed the progressive fibrotic phenotype (PFP). Their early recognition may facilitate access to antifibrotic therapies to prevent or slow progression. Macrophages/monocytes within the lung orchestrate the progression and maintenance of fibrosis. A novel role for monocyte-derived macrophages during tissue damage and wound healing is the expression of collagens. We examined Collagen 1a1 expression in airway macrophages from ILD patients at diagnosis. COL1A1 mRNA levels from BAL cells were elevated in IPF and Non-IPF patients. The presence of a UIP pattern and a subsequent progressive phenotype were significantly associated with the higher BAL COL1A1 levels. In Non-IPF patients, higher COL1A1 levels were associated with a more than twofold increase in mortality. The intracellular localisation of COL1A1 in airway macrophages was demonstrated by confocal microscopy in CD45 and CD163 co-staining assays. Additionally, airway macrophages co-expressed COL1A1 with the profibrotic SPP1 gene product osteopontin. The levels of SPP1 mRNA and OPN in the BAL were significantly higher in IPF and Non-IPF patients relative to healthy. Our results suggest that profibrotic airway macrophages are increased in the BAL of patients with IPF and other ILDs and co-express COL1A1 and OPN. Importantly, COL1A1 expression by pro-fibrotic airway macrophages could be a marker of disease progression and poor survival in ILDs.

Highlights

  • Interstitial Lung Disease (ILD) is a broad term currently used to include more than 200 different disease entities [1]

  • We have previously observed that mRNA levels of Collagen 1a1 (COL1A1) are detectable in bronchoalveolar lavage (BAL) cells and are elevated in idiopathic pulmonary fibrosis (IPF) patients relative to controls [24, 25]

  • We show that alveolar macrophages express collagen 1a1 and this is associated with worse outcomes in ILDs

Read more

Summary

Introduction

Interstitial Lung Disease (ILD) is a broad term currently used to include more than 200 different disease entities [1]. Connective tissue associated ILD (CTD-ILD) is the most common subtype, whilst idiopathic ILDs lie within the orphan characterization of rare lung diseases. The most characterized and well-studied is IPF, a lethal chronic disease [1]. IPF is distinguished by a clinical phenotype of inexorable progression and a median survival of 3 years, prior to the advent of anti-fibrotic agents [2]. Amongst other ILDs, disease behaviour is strikingly diverse, ranging from self-limited, reversible to progressive, IPF-like disease [1,2,3]. A subset of nonIPF ILD patients exhibit a more progressive disease course despite usual management, similar to IPF (PF-ILD) [3,4,5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call